



PHARMACEUTICAL 2022









PHARMACEUTICAL 2022

HCW Biologics Inc. Rank 131 of 475



The relative strengths and weaknesses of HCW Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HCW Biologics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of HCW Biologics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 15%, being 291% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	40,480
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,322
Liabilities, Non-Current	0
Other Assets	11,915
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	1,119
Research and Development	8,174
Revenues	505
Selling, General and Administrative Expense	5,194

Output Variable	Value in 1000 USD
Assets	53,515
Liabilities	2,322
Expenses	13,368
Stockholders Equity	51,193
Net Income	-12,862
Comprehensive Net Income	-12,862
Economic Capital Ratio	15%